Drugmaker says it expects to transition to ‘modest profitability’ as it receives new orders
AstraZeneca has sold more than $2.2bn (£1.64bn) of its Covid-19 vaccine in the first nine months of this year, as the drugmaker said it is set to move to “modest profitability” as new orders are received.
Britain’s biggest drugmaker has so far promised to provide the jab, which it developed with Oxford University, on a not-for-profit basis through the pandemic.
